Sales - Today Stories

LifeArc, a medical research charity, has signed an agreement to review Asthma UK’s research portfolio, aiming to identify promising projects and results which are most suited to development into treatments.  LifeArc will also advise on strategies to deliver that development.  LifeArc’s expertise in intellectual property (IP) protection, development and management will allow Asthma UK to translate its research funding into maximum benefit for patients. Dr Erika Kennington, Head of Research at Asthma UK, said: “An estimated 5.4million people in the UK live with asthma and despite the prevalence of the condition, there is still much that isn’t understood. Asthma can leave people gasping for breath and at risk of a potentially life-threatening asthma attack. Research enables a bette…

Novartis announced additional brolucizumab Phase III results from year two that reaffirmed its positive year one findings. Brolucizumab met its primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal outcomes at year one (48 weeks)1,2. Secondary endpoints at year two (96 weeks) reaffirmed superiority of brolucizumab 6 mg in reduction of retinal fluid, an important marker of disease activity in patients with neovascular age-related macular degeneration (nAMD)1,3. Approximately 20 to 25 million people are affected by nAMD, also known as wet AMD, a leading cause of blindness worldwide4,5.   The year two HAWK and HARRIER findings demonstrated that fewer patients with nAMD had intra-retinal fluid (IRF) and/or…

EB8018, the lead investigational candidate, targets Crohn’s disease with potential for other GI disorders ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.   “We are delighted to sign this agreement for EB8018, our most advanced candidate that represents a non-antibiotic, non-steroidal, non-immunomodulatory approach for the treatment of GI d…

Selexis SA and Berkeley Lights, Inc. today announced a collaboration around the acquisition of Berkeley Lights’ Beacon® optofluidic platform. The partners will leverage the technology to accelerate cell line development (CLD) with the Selexis SUREtechnology Platform™. Selexis scientists have extensively evaluated the Beacon technology and will now further incorporate it into the SUREtechnology Platform workflow. Utilizing the Beacon’s optofluidic and single cell analysis technology, the Selexis team has significantly shortened the time required to identify and select the optimal cell line manufacturing clones within the CLD process.   “We are very enthusiastic about the timeline advantages that the Beacon platform will bring to our SUREtechnology Platform,” said Igor Fisch, PhD, chi…

LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, today announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA ) for its Christensenella patent family. Christensenellais a recently discovered family of gut bacteria. Considered a keystone taxon in the human gut microbiome, it represents a major opportunity in the fight against obesity, metabolic disorders and other high-impact diseases. Christensenella and microbiome modulation is an innovative approach with the potential to unlock a wide range of therapeutic applications. By securing a license for the Christensenella patent, LNC has bolstered its strategy for developing innovative therapeutic approaches based on this new family of bacteria. "…

eXmoor pharma and MeiraGTx are delighted to announce an extension to their strategic collaboration.   eXmoor is providing process development services from its Commercialisation Laboratories at Future Space, Bristol. Two streams of work have focused on development of the MeiraGTx adherent and suspension cell process platforms and have demonstrated yield improvement as well as scale up towards commercial supply.   This collaboration is the next step in the relationship following eXmoor’s assistance in the design and implementation of MeiraGTx’s new Gene Therapy Facility in central London. Managing director of eXmoor, Angela Osborne said “The synergy with the Consultancy business keeps our Lab Team focused on the end game of GMP manufacturing and I’m very pleased that we can b…

The European specialty pharmaceutical company launches its new name to support its strategic vision   Neuraxpharm, a leading European specialty pharmaceutical company, is pleased to announce its new name, having rebranded from NuPharm Group. This exciting next chapter for the company positions Neuraxpharm as a single and differentiated CNS-oriented firm within the European pharmaceutical industry. Neuraxpharm develops and commercializes branded and generic pharmaceuticals for the treatment of disorders that affect the central nervous system (CNS). With over 100 CNS molecules, the company offers a wide range of effective, differentiated and affordable CNS treatment options to patients, healthcare professionals and industry partners. Neuraxpharm has a direct presence in Germany, Spai…

·        Deal includes global rights to pegfilgrastim biosimilar, Pelmeg® with a potential global market worth $4.5bn1 ·        Mundipharma acquires 100% ownership from parent company Infarco ·        As a leader in biosimilars in Europe, today’s deal deepens Mundipharma’s biosimilars platform beyond commercial excellence to development ·        Mundipharma estimates that through its existing partnership with Celltrion – Remsima® and Truxima® have saved healthcare systems approximately €330m2   Cambridge, UK, 10th October 2018.  The Mundipharma global network of independent associated companies has today added development capabilities to…

Hatfield, UK | Porto, Portugal | 08 October 2018 – Bial and Eisai have today announced new sub-analysis data from the Euro-Esli study, that confirms that the effectiveness of eslicarbazepine acetate monotherapy is significantly greater compared with eslicarbazepine acetate as adjunctive therapy in adults with focal-onset epilepsy based on clinical practice.[1] Whilst this may be expected, given that patients managed on monotherapy will tend to be less refractory to treatment, it provides real-world substantiation for the value of eslicarbazpine acetate as monotherapy in newly diagnosed patients. The data, which add to the body of evidence on eslicarbazepine acetate as monotherapy were published today in Acta Neurologica Scandinavica.1   The Euro-Esli study presents the largest clini…

Allergan plc (NYSE: AGN) today announced the initiation of two global clinical research programs for brazikumab, an investigational drug being studied for inflammatory bowel disease (IBD). INTREPID (Crohn's disease) and EXPEDITION (ulcerative colitis), will evaluate the safety and efficacy of brazikumab and will investigate the role of biomarkers in determining a predictive response of brazikumab in patients with IBD. They are the first active comparator studies of an IL-23 inhibitor therapy in IBD to evaluate biomarkers as potential predictors of treatment response and the first randomized comparison of an IL-23 inhibitor versus HUMIRA® (adalimumab) in Crohn's disease and ENTYVIO® (vedolizumab) in ulcerative colitis. Despite advancements in IBD treatments, up to 80 percent of patien…

GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 1,900,000 American Depositary Shares (“ADSs”), representing 22,800,000 ordinary shares of GW, at a price to the public of $158.00 per ADS on the Nasdaq Global Market, raising gross proceeds of approximately $300 million (before deducting underwriting discounts, commissions and offering expenses).  GW has granted the underwriters a 30-day option to purchase up to an additional 285,000 ADSs at the public offering price less underwriting discounts and commissions.  Closing of th…

·         Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio1 to 15 companies Arix commits $11 million (£8.4 million)2 for 11.2% ownership stake Co-investment with strategic partner Takeda and leading venture capital investors Arix further strengthens position in oncology; investment in VelosBio increases oncology portfolio3 to 5   Arix Bioscience plc (LSE: ARIX) (“Arix” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that it has invested in new Group Business, VelosBio Inc. (“VelosBio”), a next-generation oncology company, developing novel antibody-drug conjugates (“ADCs”) to treat haematological cancers and solid tumours…

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies. WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics. Under the terms of the agreement, I-Mab has rights to use the proprietary WuXiBody™ Platform to research, develop and commercialize three bispecific antibodies generated from I-MAB's proprietary pipeline. WuXi B…

Nutriband Inc. (OTCQB: NTRB), is pleased to announce it has signed the definitive acquisition agreement to acquire Carmel Biosciences, Inc.  The acquisition is expected to be valued at approximately $2,700,000 and will be paid in company stock in the amount of 350,000 restricted common shares. According to the deal, Nutriband will acquire the NDA and ownership rights to FDA approved Prexxartan™, the ownership and rights to develop and market Carmel's pipeline including CAR-509, CAR-510, CAR-511 and CAR-512 currently in Pre IND phase plus rights to Carmel's clinically tested nutraceutical line.  This includes MET-191, a nutritional supplement which has demonstrated benefit of lipid management, appetite control, and weight management, while improving factors that contribute to the…

On the occasion of the 73rd Session of the United Nations General Assembly (UNGA 73), Royal Philips (NYSE :PHG , AEX: PHIA), a global leader in health technology, today announced the successful development of the 'Augmented Infant Resuscitator (AIR)' – an add-on device for conventional neonatal bag-valve-mask (BVM) resuscitators that helps caregivers to effectively resuscitate asphyxiated newborn babies. Developed in collaboration with the Consortium for Affordable Medical Technologies (CAMTech) at Massachusetts General Hospital Global Health, the Philips Augmented Infant Resuscitator aims to reduce neonatal mortality, especially in parts of the world that are underserved in terms of healthcare. It is expected to be available in limited volume in selected markets prior to scaling up availa…

Valent U.S.A. LLC and Nufarm Americas, Inc. announced today the two companies have signed a 5-year distribution agreement extending Nufarm Americas' position as exclusive distributor of a broad portfolio of Valent branded products.  The agreement covers all Valent products for the professional turf and ornamental (T&O), aquatic, and industrial vegetation management (IVM) markets in the United States.  This agreement continues the distribution partnership Valent and Nufarm established in 2014. "This agreement between Valent and Nufarm ensures continued innovation, service, and support to our T&O, IVM, and aquatics customers, said Matt Plitt, executive vice president and chief operations officer for Valent.  "The history of the two organizations working together is so…

Thursday 20th September saw the ninth PM Society Digital Awards take place at The Brewery in London. 450 guests sat down to dinner before the winners were announced by the voice of the Lotto Alan Dedicoat and comic host Ramesh Ranganathan. There was an even spread of winners across the categories, echoing last year’s trend with no one agency or company sweeping up more than 2 Golds. This year the evening ended with the announcement of the first Pharma Digital Partner award which was won by Norgine’s Kym Jacks Bryant who beat finalists Mary Andrews from GSK and Kasper Kofod from Novo Nordisk.  Best Digital Project or Account Manager this year was won by Four Health’s Sam Bradford Smith and the Best Agency Digital Team was from Insypher. This year 3 agencies stood out at the top of th…

Aralez Pharmaceuticals Inc. ("Aralez" or the "Company") announced today that it and certain of its affiliates have entered into purchase agreements with two separate stalking-horse purchasers to sell their main operating businesses:  an agreement to sell its VIMOVO® royalties and Canadian operations to Nuvo Pharmaceuticals Inc. ("Nuvo") in a transaction valued at U.S.$110 million, subject to customary adjustments, and an agreement to sell its TOPROL-XL® Franchise to its secured lender, certain funds managed by Deerfield Management Company, L.P. ("Deerfield"), in a transaction valued at U.S.$130 million, subject to customary adjustments. Deerfield has also provided a commitment to finance Nuvo's transaction with the Company. Each of Nuvo and Deerfield has agreed to serve as "stal…

American Associated Pharmacies (AAP), an independent pharmacy cooperative with over 2,000 pharmacy members, today announced it has signed a definitive agreement to acquire the remaining 50 percent interest in the joint venture of Arete Pharmacy Network. Arete Pharmacy Network is a quality-focused national Pharmacy Services Administrative Organization (PSAO), concentrated on the success and profitability of independent and community pharmacies. The transaction closed on Sept. 12, 2018. Arete Pharmacy Network was formed in 2016 with a total of 2,250 stores; it has since grown significantly with over 2,800 pharmacies. This makes Arete Pharmacy Network the fourth largest PSAO in the nation. In December 2016, Arete Pharmacy Network further expanded its geographical footprint through the acquis…

Mitra Biotech today announced a partnership with Glenmark Pharmaceuticals focused on advancing Glenmark's proprietary immuno-oncology drug pipeline utilizing Mitra's CANscriptTM platform. CANscript is a human, immune-relevant ex vivo platform that allows drug developers to understand drug performance in human tissue, which in turn allows for an informed approach to clinical development and patient response. CANscript recreates the in vivo tumor microenvironment, maintaining the heterogeneity of the tumor while preserving its immune compartment. This uniquely positions the platform to provide drug developers with answers to mechanistic questions about their immuno-oncology drug candidates and prioritize the most promising candidates for advancement into clinical trials. "Glenmark recogniz…